艾司西酞普兰与文拉法辛缓释剂治疗抑郁症的比较研究

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (10): 1174-1178.

艾司西酞普兰与文拉法辛缓释剂治疗抑郁症的比较研究

王鹤秋, 任志斌, 王素珍

浙江省立同德医院精神科,杭州 310012,浙江

收稿日期:2011-07-25 修回日期:2011-10-06 出版日期:2011-10-26 发布日期:2011-11-02
作者简介:王鹤秋,男 ,本科,副主任医师,研究方向:临床精神病学。Tel: 0571-88695639, E-mail: wangheqiu2008@163.com

A clinical observation of escitalopram and venlafaxine-extended-release (XR) general in the treatment of outpatients with depression

WANG He-qiu, REN Zhi-bin, WANG Shu-zhen

Department of Psychiatry,Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang,China

Received:2011-07-25 Revised:2011-10-06 Online:2011-10-26 Published:2011-11-02

摘要/Abstract

摘要： 目的: 评价和比较艾司西酞普兰与文拉法辛缓释剂治疗抑郁症的临床疗效和安全性。方法: 将89例门诊抑郁症患者分别随机给予艾司西酞普兰和文拉法辛缓释剂治疗,在2周内逐步增高剂量至 20 mg/d 或 150 mg/d,在治疗前后用蒙格马利-阿斯伯格抑郁评定量表(MADRS)、临床整体印象改善评分(CGI)和副反应量表(TESS)评定疗效和不良反应。结果: 43例门诊抑郁症患者应用艾司西酞普兰,46例患者应用文拉法辛缓释剂,经治疗后MADRS的总分较治疗前均有统计学差异,第1周时艾司西酞普兰与文拉法辛缓释剂临床缓解率和有效率比较有统计学差异(P<0.01),治疗第8周时艾司西酞普兰与文拉法辛缓释剂临床缓解率分别是 51.28%、44.44%; 有效率为 71.79%、61.11%;两组不良反应轻且发生率少。结论: 艾司西酞普兰与文拉法辛缓释剂均能安全、有效地治疗抑郁症。相比而言,艾司西酞普兰起效更快,不良反应较少,可作为门诊治疗抑郁症的首选用药。

关键词: 艾司西酞普兰, 文拉法辛缓释剂, 抑郁症, 疗效, 安全性

Abstract: AIM: To observe and compare the efficacy and safety of escitalopram and venlafaxine-extended-release (XR) in the treatment of outpatients with depression. METHODS: 89 outpatients with depression were randomized to receive escitalopram or venlafaxine-extended-release (XR) for 8 weeks, and dose titrated from 10 mg/d or 75 mg/d to a maximum of 20 mg/d or 150 mg/d respectively within the first 2 weeks of treatment. Effects and adverse events were evaluated with MADRS, HAMA, CGI and TESS before and after the treatment. RESULTS: After 8 weeks treatment, total scores of MADRS of 39 patients with escitalopram or 36 venlafaxine-XR both showed significant change compared with baseline, and escitalopram. After 8 weeks treatment, percentage of recovery were 51.28% and 44.44% respectively, while significant improvement percentage were 71.79% and 61.11% in each group. CONCLUSION: Escitalopram and venlafaxine-extended-release (XR) both are effective and safe antidepressants, and escitalopram has a faster and better effectiveness profile in treatment of depression.

Key words: Escitalopram, Venlafaxine-extended-release, Depression, Efficacy, Safety

中图分类号:

R749

王鹤秋, 任志斌, 王素珍. 艾司西酞普兰与文拉法辛缓释剂治疗抑郁症的比较研究[J]. 中国临床药理学与治疗学, 2011, 16(10): 1174-1178.

WANG He-qiu, REN Zhi-bin, WANG Shu-zhen. A clinical observation of escitalopram and venlafaxine-extended-release (XR) general in the treatment of outpatients with depression[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(10): 1174-1178.

参考文献

[1] Chen F, Larsen MB, Sánchez C,et al.The S-enantiomer of R,S-Citalopram,increases inhibitor binding to the human serotonin transporter by an allosteric mechanism.Comparison with other serotonin transporter inhibitors[J]. Eur Neuropsychopharmacol,2005,15(2):193-198.
[2] Wellington K, Perry CM. Venlafaxin-ER : a review of its use in the man agement major depression [J]. CNS Drugs,2001,15(8):643-669.
[3] Thase ME, Entsuah AR,Rudolph RL. Remission rats during treatment with venlafaxine or selective serotonin reuptake inhibitors[J]. Br J Psychiatry, 2001,178:234-241.
[4] Sánchez C, Bøgesø KP, Ebert B, et al. Escitalopram Versus citalopram:the surprising role of the R-enantiomer[J].Psychopharmacology, 2004, 174(2):163-176.
[5] Mentgonmery SA, Huuson AKT, Bothmer J. A randomized study comparing escitalopram with venlafaxineXR inpatients in primary care with major depressive disorder[J]. Neuropsychobiology, 2004,50(1):57-64.
[6] 顾牛范,李华芳,舒良,等.文拉法辛缓释剂治疗抑郁的双盲,随机平行、对照、多中心临床研究[J].中国新药与临床杂志,2002,21(2):66-71.
[7] Wade A, Friis Andersen H. The onset of effect for escitalopram and its relevance for chinical management of depression[J].Curr Med Res Opin,2006,122(11):2010-2110.
[8] Norman TR, Leonard BE. Fast-acting antidepressants:Can the Need be Met[J] ？ CNS Drugs, 1994,2(2):120-131.
[9] Posternak MA, Zimmerman M. Is there a delay in the antidepressanteffect? A meta-analysis[J]. J Clin Psychiatry, 2005,66(2):148-158.
[10] Kaspera S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis[J]. Int Clin Psychopharmacol,2006, 21(2):105-110.
[11] Kasper S, de Swart H, Andersen HF. Escitalopram in the treatment of depressed elderly patients[J]. Am J Geriatr Psychiatry ,2005,13 (10):884-891.
[12] Kennedy SH, Andersen HF, Thase ME. Thase. Escitalopram in the treatment of major depressive disorder: A meta-analysis[J]. Curr Med Res Opin, 2009,25(1):161-175.
[13] 朱毅平,金学敏.艾司西酞普兰联合左旋甲状腺素钠治疗抑郁症伴发亚临床甲状腺功能减退33例[J]. 医药导报,2010,29(9):1154-1156.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[3]	刘敏, 孔祥, 章叶, 顾逸飞, 项雪梅, 黄凯. 经口吸入制剂在中国健康受试者生物等效性试验中的安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(10): 1131-1138.
[4]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[5]	梁美芳, 陈庆状, 杨沛群, 王勇. 基于真实世界的阿托伐他汀仿制药和原研药防治缺血性脑卒中/短暂性脑缺血发作的有效性和安全性比较[J]. 中国临床药理学与治疗学, 2022, 27(7): 785-792.
[6]	晏玉奎, 胡建琴, 张冰. 新型和传统抗癫痫药物治疗新诊断部分性癫痫的临床研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 793-799.
[7]	何滕, 许向阳, 徐祥清, 刘存明, 杨春. 氯胺酮治疗抑郁症的过去、现在及未来[J]. 中国临床药理学与治疗学, 2022, 27(10): 1125-1132.
[8]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[9]	王叶情, 王宇红, 刘检, 赵洪庆, 邹蔓姝. 胆囊收缩素与抑郁症的相关性研究进展[J]. 中国临床药理学与治疗学, 2021, 26(6): 672-679.
[10]	陈颖, 袁勇贵. 中药单体、药对、复方、中成药治疗抑郁症研究进展[J]. 中国临床药理学与治疗学, 2021, 26(5): 586-593.
[11]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[12]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[13]	金晶, 程虹. 线粒体能量代谢参与抑郁症发病的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1193-1199.
[14]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[15]	冯睿，张佳莉，赫明超，李钺，张岩. 中药及其活性成分防治抑郁症的药理靶点与临床应用[J]. 中国临床药理学与治疗学, 2020, 25(4): 467-474.